Sphera Funds Management LTD. lifted its position in Vistagen Therapeutics Inc (NASDAQ:VTGN) by 22.0% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 1,673,918 shares of the company’s stock after acquiring an additional 302,026 shares during the quarter. Sphera Funds Management LTD. owned about 0.05% of Vistagen Therapeutics worth $2,427,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several research firms recently issued reports on VTGN. Zacks Investment Research cut shares of Vistagen Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 7th. Maxim Group set a $6.00 target price on shares of Vistagen Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 30th. Oppenheimer set a $6.00 target price on shares of Vistagen Therapeutics and gave the company a “buy” rating in a research note on Tuesday, September 4th. Finally, ValuEngine upgraded shares of Vistagen Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. One analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $8.30.
Shares of NASDAQ VTGN opened at $1.76 on Friday. The firm has a market capitalization of $52.80 million, a P/E ratio of -1.59 and a beta of -1.58. Vistagen Therapeutics Inc has a one year low of $0.81 and a one year high of $2.44.
Vistagen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings results on Monday, October 29th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.13). As a group, analysts expect that Vistagen Therapeutics Inc will post -1.1 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Sphera Funds Management LTD. Has $2.43 Million Position in Vistagen Therapeutics Inc (VTGN)” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/12/08/sphera-funds-management-ltd-has-2-43-million-position-in-vistagen-therapeutics-inc-vtgn.html.
Vistagen Therapeutics Company Profile
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
See Also: Stock Symbols and CUSIP Explained
Want to see what other hedge funds are holding VTGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vistagen Therapeutics Inc (NASDAQ:VTGN).
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.